Track Generation Bio Co. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Generation Bio Co. GBIO · Stock Open Generation Bio Co. in new tab

5.34 USD
EPS
-9.37
P/B
0.71
ROE
-80.81
Beta
2.01
Target Price
5.25 USD
Loading chart...
Key Metrics
EPS-9.37
Book Value7.51
Price to Book0.71
Debt/Equity51.61
% Insiders14.292%
Growth
Revenue Growth-0.79%
Estimates
Forward P/E-3.99
Forward EPS-1.34
Target Mean Price5.25

DCF valuation

Model fair value for Generation Bio Co. (GBIO)
Result
Sign in to run the valuation for GBIO.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
mean target 5.25 USD (low 5.00, high 5.50)
Low 5.00
Mean 5.25
High 5.50
Price 5.34
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Generation Bio Co. Logo Generation Bio Co. Analysis (GBIO)

United States Health Care Official Website Stock

Is Generation Bio Co. a good investment? Generation Bio Co. (GBIO) is currently trading at 5.34 USD. Market analysts have a consensus price target of 5.25 USD. This suggests the asset is currently trading above analyst expectations.

Investor FAQ

Does Generation Bio Co. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Generation Bio Co.?

Generation Bio Co. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

Company Profile

Generation Bio Co., a biotechnology company, discovers, develops, and commercializes redosable therapeutics that reprogram T cells in vivo to reduce or eliminate the production and persistence of autoreactive T cells. It develops cell-targeted lipid nanoparticles (ctLNP) to selectively deliver small interfering RNA (siRNA) T cells to selectively delivery, intracellular, and genetically precise mechanism of target engagement could unlock a series of high-value historically undruggable disease-driving genes in autoimmunity. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Exchange Ticker
NMS (United States) GBIO
Trades
Dividend History paid per year (USD)
No dividend history available.
Stock Splits
Split Date Split Ratio to 1
July 22, 2025 1:10
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion